Summary: Low-molecular-weight heparins provide new options for outpatient management of deep venous thrombosis. Because elderly patients with cancer are at increased risk of developing deep venous thrombosis, outpatient therapy for treatment of deep venous thrombosis may be important in this population. We compared the severity of illness, outcomes, and cost of deep venous thrombosis in elderly patients with cancer to those seen in younger patients with cancer. We examined all 766 episodes of deep venous thrombosis treated at the University of Texas M.D. Anderson Cancer Center between January 1, 1994 and December 31, 1996. Severity of illness level and predicted risks of mortality and readmission were obtained from a commercially available disease staging system (Inforum System). Observed outcomes and cost were based on data collected from the 766 episodes of deep venous thrombosis at our institution. One hundred nineteen (16%) episodes of deep venous thrombosis occurred in patients 70 years of age or older.
The severity of illness scale (1-5, least-most severe) were identical (3.7) in the 3 groups studied (< 70 years, 70-79, years and &ge;80 years). The predicted risk of death during hospitalization (6%, 9%, 8%, respectively, by group, P = 0.12) and readmission in 30 days (5%, 4%, 3%, respectively, P = 0.04) were similar among the groups. The observed death rates during hospitalization were 5%, 6%, and 6%, respectively ( P = 0.91), and the rates of hospitalization for deep venous thrombosis recurrence were 22%, 16%, and 28%, respectively ( P = 0.27). The similarities in outcomes and resource use between elderly and younger patients suggest that elderly patients with cancer are not at greater risk of serious clinical outcomes or a prolonged clinical course. There is significant potential for outpatient management of these patients. Key Words: Deep venous thrombosis&mdash;Elderly patients&mdash;Cancer&mdash;Resource use&mdash; Severity of illness&mdash;Outcomes.
Deep venous thrombosis (DVT) and pulmonary embolism (PE) present common and potentially serious clinical challenges. The estimated incidence of DVT and PE in the United States is approximately 450,000 and 355,000 cases per year, respectively. Because thromboembolism may be overlooked because of its sometimes vague complaints and symptoms, the actual incidence may be much higher than presently documented. Pulmonary embolism is often associated with increased mortality, and it contributes to approximately 240,000 deaths annually in the United States (1, 2) .
The recent development of low-molecular-weight heparins for therapy for thromboembolic disease now permits outpatient management of some patients with this problem (3, 4) . Thromboembolic disease is common among patients with cancer; therefore, outpatient management has the potential to affect the lives of many patients with cancer. Because ambulatory care is preferred to hospitalization by many patients with cancer, the use of low-molecular-weight heparins in this setting could lead to greater patient satisfaction and improved quality of life as well as to reduced cost and decreased exposure to nosocomial infections.
There are a number of factors related to increased risk of development of thromboembolic disease. Among these are recent surgical intervention, older age, underlying malignancy, obesity, prolonged immobilization, prolonged anesthesia, coagulation abnormalities, cardiovascular disease, previous thromboembolic disease, fractures of the pelvis, hip, or leg, and high-dose estrogen use (5-7).
Because of their multiple risk factors, elderly patients with cancer constitute a particularly important population with respect to DVT. Recent projections show that the proportion of elderly persons in the US population is increasing. The current elderly population (65 years and older) is 31.1 million or about 12.5% of the US population (8) . It is projected that one in five individuals will be 65 years or older in 2030. Aging is a high risk factor for cancer, and more than 58% of all cancers are diagnosed in the elderly (9) . The incidence rate for those 65 years or more is 2,085.3 per 100,000 persons compared with 193.9 per 100,000 for those younger than 65 years of age. This is 10 times greater risk than for persons younger than 65 years of age.
Because aging is a risk for both the development of malignancy and thromboembolic disease, increases in the size of the elderly population will likely result in an increased number of cancer patients with thrombosis. Unfortunately, however, there are scarce data available in this population to aid in the development of outpatient strategies for treatment of thromboembolism. Specifically, it is not known whether elderly patients with cancer and DVT differ from their younger counterparts with respect to severity of illness and risk of associated mortality or readmission. To further the development of these treatment strategies, we retrospectively compared severity of illness, mortality, hospital readmission, and resource use in elderly patients (~:70 years) with cancer and DVT to the same parameters in younger patients (<70 years) with cancer. is a comprehensive cancer center, and all patients had a cancer diagnosis. Recurrence of DVT was defined as the presence of one of the following: a defect of intraluminal filling detected in more than one projection on venography; an abnormal flow pattern, difference in angulation of flow, cessation of flow, or development of collaterals in one projection (usually anterior) on nuclear flow study; a lack of compressibility at a new site or a definite increase in thrombus size as detected on compression ultrasonography. Cost was computed using department-and servicespecific cost algorithms for each of the services provided during the hospitalization for treatment of DVT. Severity of illness level and predicted risks of mortality and readmission were obtained from the Inforum System (The Medstat Group, Nashville, TN, USA), a commercially available product based on the disease staging method of severity adjustment. Using this system, DRG-, ICD9-, and CPT-coded diagnoses and procedures for individual patients were used to compute severity of illness levels and risk scores based on comparisons to the observed outcomes of similar patients from large normative databases.
METHODS

Episodes of DVT
RESULTS
Seven hundred sixty-six episodes of hospitalization for treatment of DVT were identified. Of those, 119 (16%) occurred in patients with cancer who were 70 years of age or older. The median age of this elderly group was 74 years, with a range of 70-87 years. Fifty percent were male. Eighty-three percent were white, 9% had a Spanish surname, and 8% were black. The most common underlying malignancies in this group were genitourinary (19%), unknown primary (12%), and gynecologic malignancy (10%). This was similar to the distribution of the entire group (15% genitourinary, 12% gynecologic malignancy, and 5% unknown primary). In this elderly cohort, 9% had multiple primary malignancies.
Most of these patients (79%) received cancer treatment once referred to UTMDACC, and nearly half had received chemotherapy (43%) or surgery (41%) before their referral to UTMDACC.
The mean severity of illness levels were the same in each of the three groups analyzed. The predicted risk of death during hospitalization and readmission in 30 days were similar among the age groups, as were the observed rates of mortality during hospitalization and recurrence of DVT. However, the observed rate of hospital readmission in 30 days exceeded the predicted risk by a factor of more than 4, perhaps because of the complexity of the patients seen and the aggressive therapy used in our comprehensive cancer center. The mean duration and mean cost of hospitalization between the groups were also similar (Table 1) .
Overall, survival after the diagnosis of DVT was not statistically different among patients in the three age groups. However, as would be expected from an analysis including the very old, the survival curve for younger patients begins to diverge after 15 months when the elderly patients reach the limits of life expectancy. (Fig. 1 ).
DISCUSSION
By the year 2005, 13.1 % of the population in the United States is expected to be over the age of 65 (10) . The 80-plus age group is now growing faster than any other in the United States. Because of an increase in life expectancy and improved functional status in many elderly, these patients are often diagnosed and undergo aggressive antineoplastic treatment regimens. However, despite their improved clinical status, these elderly patients often exhibit multiple comorbidities. Thus, the risk of serious medical complications may be a significant clinical issue, particularly in the outpatient setting with its inherently less vigilant monitoring. Unfortunately, there are little data to support the resolution of these issues in elderly patients with cancer. As a preliminary attempt to address these issues, we investigated whether elderly patients with cancer required longer hospital stays or had increased mortality or cost associated with DVT. If these surrogate measures of serious complications were not increased in elderly patients compared to younger ones, further development of outpatient treatment strategies of DVT in elderly patients with cancer is probably warranted. Our results suggest that elderly patients with cancer and DVT are not at greater risk of serious clinical outcomes or a prolonged clinical course compared to their younger counterparts and that further study of outpatient strategies is justified. This is encouraging for a number of reasons. First, during the last 5 years, ambulatory oncologic care has become the standard in most communities. Because of the scientific innovations in the pharmaceutical industry, medical technology, and home care experience, various inpatient treatment have been moved to the ambulatory venue.
Second, patients are often happier and, perhaps, healthier in their own homes. The majority of our oncology patients prefer to be at home as much as possible. Many come daily to our Ambulatory Treatment Center to receive chemotherapy and other infusions. This allows them to spend more time in a familiar environment, surrounded by their family and friends. Furthermore, many are still in the workforce and ambulatory treatment allows flexibility in their work schedules. This may be a significant factor considering the financial burden that often accompanies the diagnosis of cancer and other chronic diseases. For patients who are not working or unable to work, ambulatory treatment allows them to maintain better control of their daily activities. Often patients feel more content and less anxious in familiar surroundings. Hospitals often appear utilitarian and impersonal to patients and families. Hospitalization also exposes the patients to potential nosocomial infections that are not present in the ambulatory setting.
Finally, from an institutional perspective, ambulatory care has the potential to decrease cost. Reimbursement may be improved in an ambulatory setting but may vary depending on the healthcare provider. Centers excelling in ambulatory treatment may also be used as a strategic marketing tool in vying for managed care contracts. The ultimate consumers, the patients, often influence these decisions. With greater numbers of elderly patients with cancer, it is imperative that this subpopulation undergoes more study with greater emphasis on development of ambulatory strategies benefiting this group.
Although the potential for ambulatory management of these patients is undeniable, consideration must be given to other factors influencing treatment outcomes of DVT.
Functional status, the response of the malignancy to treatment, and the presence and status of other comorbidities may influence both treatment outcomes and cost of episodes of DVT. These factors may influence the decision of hospitalization versus potential outpatient management of the episode of DVT with low-molecularweight heparin.
For the healthy elderly patient with a good functional status and few or no comorbidities, outpatient treatment of DVT may be appropriate. However, in other subpopulations of the elderly, inpatient management may be necessary. Defining appropriate low-risk groups of elderly patients with cancer for development of outpatient treatment strategies for DVT is currently in progress.
